Andrew Dunn

NEW: Recursion is abandoning or pausing 5 drug programs, cutting nearly half its pipeline — including what were its most clinically advanced efforts $RXRX -10% this morning Details: https://t.co/bnJJtEjk1M

“Anybody can spin up big dreams about what might be possible with AI and then get dinged for hype,” Iambic CEO Tom Miller told me. “We really like to lean into what we’ve actually done.” More here in my @endpts latest: https://t.co/oDBlHBbySX

This is a fantastic inside look at the rise and fall of SalioGen from @RLCscienceboss, a biotech that was trying to figure out how to precisely insert whole genomes: https://t.co/eV6sZ090WU

I'll selfishly add, as a journalist covering the AI bio world closely, let me know as well if you're a scientist trying out these tools — good, bad and ugly. My email: [email protected] My latest @endpts on the launch of Future House's AI agents: https://t.co/RF3jy2KH9s

Sam Rodriques @SGRodriques

"Inviting skeptical scientists to try for free" 😂 Great coverage of our Platform launch by @AndrewE_Dunn and @endpts. For the skeptical scientists in the audience: we're skeptical scientists too, and we're with you! If it doesn't work for you yet, let us know!

RT @PearlF: AD asked if we'll see significant scientific discoveries from AI in 2025, @pdhsu's response: "You need a 'world model' of biolo…

RT @michellearning: @pdhsu thanks for the shoutout on @endpts with @AndrewE_Dunn 🦾 we'll be sharing some exciting updates on physical AI fo…

NEW: Stately Bio is now launching after 3 years in stealth, CEO Frank Li, told me. Li previously led the machine-learning group at Calico, leaving in 2021 to found Stately. He's raised a $12M seed for a new way to study cells w/ AI: https://t.co/sFw5Bdak9U

This was a fun one — new Endpoints Slack interview with @pdhsu: https://t.co/teqQ87ahlk

Here's something new: our first-ever Post-Hoc Live happens tomorrow at noon ET Watch @ArmstrongDrew, @maxonwifi, and @annajbwn talk pharma & tariffs ... and doing it live: https://t.co/FISHJTNCk0

IN 10 MINUTES: I'll be hosting a fireside chat with Beam Therapeutics CEO @john_evans3 We'll talk about the current and future of gene editing, FDA/NIH changes and much more. Register for free to join us live: https://t.co/phnpzr833D

Exclusive: Axiom has raised a $15 million seed round, advancing its AI models for drug toxicity predictions I talked with CEO @bwhite5290 ahead of the startup's official launch: https://t.co/vvvE7pJu7E

Biotech investors seem to be reaching a boiling point with the market downturn — and a new fund is launching to target flailing biotechs on the public market My @endpts latest on Alis Biosciences' debut: https://t.co/BYiqSjWVEt

For the drug industry, President Donald Trump’s tariffs haven’t started to really hurt. At least not yet. My latest on what we learned today in how drugmakers are preparing for tariffs: https://t.co/CuTeeUPJIq

Along with a new Lilly partnership, BigHat extended its Series B from $75M to over $120M Preparing to be in the clinic next year: https://t.co/cWmqEa20kF

Scoop: The London biotech Charm Therapeutics is looking for a new top executive to replace founding CEO Laksh Aithani: https://t.co/elUIkjCEu3

NEW: With M&A and IPO exits now largely off the table in biotech, what's left? I walk through 10 moves that biotech CEOs are likely contemplating in response to the market turmoil: https://t.co/iO6FyfKu4D

For his post-Pfizer era, Mikael Dolsten is already working with ~10 life science companies, ranging from large businesses to new startups That includes Formation Bio, where he'll lead a drug-picking committee as an advisor. My latest at @endpts: https://t.co/kvBT2f3Bp3